Center for Translational Medicine and Immune Diagnostics Laboratory, Medical Department I, Marien Hospital Herne, University Hospital of the Ruhr-University Bochum, Hölkeskampring 40, 44625, Herne, Germany.
Berlin Institute of Health at Charité - Universitätsmedizin Berlin, BIH Center for Regenerative Therapies (BCRT), Charitéplatz 1, 10117, Berlin, Germany.
J Nephrol. 2021 Aug;34(4):1025-1037. doi: 10.1007/s40620-021-01092-0. Epub 2021 Jul 6.
Recent data demonstrate potentially protective pre-existing T cells reactive against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in samples of healthy blood donors, collected before the SARS-CoV-2 pandemic. Whether pre-existing immunity is also detectable in immunosuppressed patients is currently not known.
Fifty-seven patients were included in this case-control study. We compared the frequency of SARS-CoV-2-reactive T cells in the samples of 20 renal transplant (RTx) patients to 20 age/gender matched non-immunosuppressed/immune competent healthy individuals collected before the onset of the SARS-CoV-2 pandemic. Seventeen coronavirus disease 2019 (COVID-19) patients were used as positive controls. T cell reactivity against Spike-, Nucleocapsid-, and Membrane- SARS-CoV-2 proteins were analyzed by multi-parameter flow cytometry. Antibodies were analyzed by neutralization assay.
Pre-existing SARS-CoV-2-reactive T cells were detected in the majority of unexposed patients and healthy individuals. In RTx patients, 13/20 showed CD4 T cells reactive against at least one SARS-CoV-2 protein. CD8 T cells reactive against at least one SARS-CoV-2 protein were demonstrated in 12/20 of RTx patients. The frequency and Th1 cytokine expression pattern of pre-formed SARS-CoV-2 reactive T cells did not differ between RTx and non-immunosuppressed healthy individuals.
This study shows that the magnitude and functionality of pre-existing SARS-CoV-2 reactive T cell in transplant patients is non-inferior compared to the immune competent cohort. Although several pro-inflammatory cytokines were produced by the detected T cells, further studies are required to prove their antiviral protection.
最近的数据表明,在 SARS-CoV-2 大流行之前采集的健康献血者样本中,存在针对严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)的潜在保护性预先存在的 T 细胞。目前尚不清楚预先存在的免疫是否也可在免疫抑制患者中检测到。
本病例对照研究纳入了 57 名患者。我们比较了 20 名肾移植(RTx)患者和 20 名年龄/性别匹配的非免疫抑制/免疫功能正常的健康个体在 SARS-CoV-2 大流行之前采集的样本中 SARS-CoV-2 反应性 T 细胞的频率。17 名 2019 年冠状病毒病(COVID-19)患者被用作阳性对照。通过多参数流式细胞术分析 T 细胞对 Spike-、Nucleocapsid-和 Membrane-SARS-CoV-2 蛋白的反应性。通过中和测定分析抗体。
在大多数未暴露的患者和健康个体中检测到预先存在的 SARS-CoV-2 反应性 T 细胞。在 RTx 患者中,13/20 例显示出至少一种 SARS-CoV-2 蛋白反应性的 CD4 T 细胞。在 12/20 例 RTx 患者中,检测到至少一种 SARS-CoV-2 蛋白反应性的 CD8 T 细胞。预先形成的 SARS-CoV-2 反应性 T 细胞的频率和 Th1 细胞因子表达模式在 RTx 患者和非免疫抑制的健康个体之间没有差异。
本研究表明,与免疫功能正常的队列相比,移植患者预先存在的 SARS-CoV-2 反应性 T 细胞的数量和功能没有差异。尽管检测到的 T 细胞产生了几种促炎细胞因子,但仍需要进一步研究来证明它们的抗病毒保护作用。